CN106075020A - 一种具有治疗糖尿病功效的灵芝复方颗粒剂 - Google Patents
一种具有治疗糖尿病功效的灵芝复方颗粒剂 Download PDFInfo
- Publication number
- CN106075020A CN106075020A CN201610446034.2A CN201610446034A CN106075020A CN 106075020 A CN106075020 A CN 106075020A CN 201610446034 A CN201610446034 A CN 201610446034A CN 106075020 A CN106075020 A CN 106075020A
- Authority
- CN
- China
- Prior art keywords
- parts
- ganoderma
- treatment diabetes
- pollen
- hippocampus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000222336 Ganoderma Species 0.000 title claims abstract description 48
- 230000000694 effects Effects 0.000 title claims abstract description 41
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 29
- 239000008187 granular material Substances 0.000 title claims abstract description 28
- 210000000582 semen Anatomy 0.000 claims abstract description 29
- 241000208340 Araliaceae Species 0.000 claims abstract description 18
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 18
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 18
- 235000008434 ginseng Nutrition 0.000 claims abstract description 18
- 241000827798 Hemerocallis citrina Species 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 15
- 210000001320 hippocampus Anatomy 0.000 claims abstract description 14
- 230000001413 cellular effect Effects 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 239000008280 blood Substances 0.000 abstract description 24
- 210000004369 blood Anatomy 0.000 abstract description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 15
- 239000008103 glucose Substances 0.000 abstract description 15
- 208000024891 symptom Diseases 0.000 abstract description 15
- 210000003734 kidney Anatomy 0.000 abstract description 12
- 235000000346 sugar Nutrition 0.000 abstract description 11
- 210000004185 liver Anatomy 0.000 abstract description 7
- 210000002700 urine Anatomy 0.000 abstract description 7
- 230000036772 blood pressure Effects 0.000 abstract description 5
- 210000000056 organ Anatomy 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 210000002784 stomach Anatomy 0.000 abstract description 4
- 230000004304 visual acuity Effects 0.000 abstract description 4
- 238000010792 warming Methods 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 230000001537 neural effect Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000000291 postprandial effect Effects 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 235000021152 breakfast Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000009928 nephrosis Diseases 0.000 description 2
- 231100001027 nephrosis Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- CDYBOKJASDEORM-HBVDJMOISA-N isomangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC1=CC(O)=C(O)C=C1C2=O CDYBOKJASDEORM-HBVDJMOISA-N 0.000 description 1
- ALKWDTQJMCZSSY-UHFFFAOYSA-N isomangiferin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)c4cc(O)c(O)cc4Oc23)C(O)C(O)C1O ALKWDTQJMCZSSY-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于保健品的制备领域,具体涉及一种具有治疗糖尿病功效的灵芝复方颗粒剂及其制备方法。按重量份数计,其主要原料组成为:灵芝10‑20份,破壁灵芝孢子粉4‑8份,桦褐孔菌5‑7份,人参4‑6份,黄花22‑26份,山药28‑32份,知母13‑17份,花粉14‑16份,玄参14‑16份,菟丝子10‑12份,黑豆8‑10份,海马3‑6份,香椿叶4‑5份。本发明的配方经科学研制,各原料之间发生协同增效作用,具有扶正固本、温肾壮阳、健胃理气、养肝明目、降血压、降血糖、降血脂、预防心血疾病、改善血糖/尿糖等症状,从根本上治疗糖尿病对全身组织器官带来的损害,特别是对眼、肾、心血管及神经系统的损害,彻底根治糖尿病。
Description
技术领域
本发明属于保健品的制备领域,具体涉及一种具有治疗糖尿病功效的灵芝复方颗粒剂及其制备方法。
背景技术
糖尿病是一种由于胰岛素分泌缺陷或胰岛素作用障碍所致的以高血糖为特征的代谢性疾病。持续高血糖与长期代谢紊乱等可导致全身组织器官,特别是眼、肾、心血管及神经系统的损害及其功能障碍和衰竭。
糖尿病肾衰竭是最常见的糖尿病慢性并发症,可严重危害人们的身体健康。糖尿病早期,由于其对肾脏的损害具有隐匿性,因此肾衰竭的症状并不明显,随着病情的发展,肾小球硬化状态变得明显,受损的肾小球个体越来越多,越到后来发展越快,最终导致蛋白尿等症状,使其进展为糖尿病肾衰竭。
现有治疗糖尿病的药物很多,但真正具有保护肾功能、减轻肾脏负担的药物却很少。
发明内容
本发明的目的在于针对现有技术的不足,提供一种具有治疗糖尿病功效的灵芝复方颗粒剂及其制备方法。本发明的配方经科学研制,各原料之间发生协同增效作用,具有扶正固本、增强免疫力、温肾壮阳、健胃理气、养肝明目、降血压、降血糖、降血脂、预防心血疾病、改善血糖/尿糖等症状,从根本上治疗糖尿病对全身组织器官带来的损害,特别是对眼、肾、心血管及神经系统的损害;并具有抗癌功效。
为实现本发明的目的,采用如下技术方案:
一种具有治疗糖尿病功效的灵芝复方颗粒剂,按重量份数计,其主要原料组成为:灵芝10-20份,破壁灵芝孢子粉4-8份,桦褐孔菌5-7份,人参4-6份,黄花22-26份,山药28-32份,知母13-17份,花粉14-16份,玄参14-16份,菟丝子10-12份,黑豆8-10份,海马3-6份,香椿叶4-5份。
优选的,所述的具有治疗糖尿病功效的灵芝复方颗粒剂,按重量份数计,其主要原料组成为:灵芝15份,破壁灵芝孢子粉6份,桦褐孔菌6份,人参5份,黄花25份,山药30份,知母15份,花粉15份,玄参15份,菟丝子11份,黑豆9份,海马5份,香椿叶5份。
一种制备如上所述的具有治疗糖尿病功效的灵芝复方颗粒剂的方法,包括以下步骤:
1)取灵芝、桦褐孔菌、人参、黄花、山药、知母、花粉、玄参、菟丝子、黑豆、海马和香椿叶,混合均匀,加入8-10倍重量的水,在80-90℃煮制30-60min后,过滤;在滤渣中加入4-6倍重量的水,在80-90℃煮制40-50min后,过滤;合并两次过滤的滤液,在70-80℃减压浓缩至相对密度为1.1-1.3的浸膏;
2)将破壁灵芝孢子粉经紫外灭菌30min后,加入浸膏中;
3)然后在步骤2)的浸膏中加入稀释剂、粘合剂,进行湿法制粒;
4)干燥,整粒,过12-20目筛,检验,包装。
所述的稀释剂由微晶纤维素、三硅酸镁按质量比5: 3混合制成;
所述的粘合剂为5%的聚维酮(PVP)溶液。
本发明所选用原料的功效在于:
1)桦褐孔菌含有大量的抗癌、降血压、降血糖、复活免疫作用的植物纤维类多糖体,可以提高免疫细胞的活力,抑制癌细胞扩散和复发,在胃肠内防止致癌物质等有害物质的吸收,并促进排泄;
2)人参的主要成分是人参皂甙,还含有人参多糖、人参蛋白质、人参挥发油、氨基酸、无机元素、肽类物质、多种维生素,有机酸、生物碱、脂肪类、黄酮类、酶类、甾醇、核苷、木质素等物质;其能降低血糖,改善血脂,升高高密度脂蛋白胆固醇,具有抗动脉粥样硬化之功效;
3)黄花含有丰富的花粉、糖、蛋白质、维生素C、钙、脂肪、胡萝卜素、氨基酸等人体所必须的养分,其能显著降低血清胆固醇的含量;黄花菜中还含有效成分能抑制癌细胞的生长,丰富的粗纤维能促进大便的排泄;
4)山药含有粘液蛋白,有降低血糖的作用,可用于治疗糖尿病,是糖尿病人的食疗佳品;能有效阻止血脂在血管壁的沉淀,预防心血疾病;
5)知母含有皂甙、黄酮类的芒果甙、异芒果甙、生物碱类的胆碱、尼克酰胺、有机酸类的鞣酸、烟酸以及四种知母多糖等;具有显著的降血糖作用;
6)花粉富含多种氨基酸、维生素A、维生素C、维生素E、活性物质以及微量元素硒、磷脂、核酸等成分;具有防治贫血、糖尿病等功效;
7)玄参含生物碱、糖类、甾醇、氨基酸、脂肪酸、挥发油、胡萝卜素和维生素A 类物质;具有清热凉血、滋阴降火、解毒功效;
8)菟丝子有补肾益精,养肝明目的作用,用于腰膝酸痛、遗精、糖尿病;
9)海马有温肾壮阳、调气活血的作用;
10)香椿叶味苦,性寒,有清热解毒、健胃理气的功效,是治疗糖尿病的良药;
11)黑豆富含对人体有益的氨基酸、不饱和脂肪酸及钙、磷等多种微量元素。有排脓拔毒、消肿止痛等功效,并有益于防治高血压、高血脂、心脏病等疾病。
12)灵芝降血糖之原理是由于促进组织对糖的利用,服用灵芝后可取代胰岛素抑制脂肪酸的释出,可改善血糖、尿糖等症状;灵芝中的水溶性多糖,可减轻非胰岛素依赖型糖尿病的发病程度;
13)灵芝孢子粉可刺激胰岛素的分泌,降低血糖浓度。
本发明与现有技术比较具有以下优点:
1)中医学认为,“出入”中的“出”指的是大、小便、汗的排泄,“入”指的是进食,“出”比“入”更为重要,如若排泄不畅,必将导致新陈代谢的产物、毒素等郁积体内,对五脏六腑(尤其是肾)造成损害;本发明在配方中加入桦褐孔菌、黄花、玄参、香椿叶,共奏清热解毒、滋阴降火、促排泄、排毒之功;
2)桦褐孔菌、人参、黄花、山药、知母、黑豆、灵芝孢子粉等共奏降血脂、降血糖、降血压之功,所有原料复配,产生协同增效作用,具有扶正固本、增强免疫力、温肾壮阳、健胃理气、养肝明目、降血压、降血糖、降血脂、预防心血疾病、改善血糖/尿糖等症状,从根本上治疗糖尿病对全身组织器官带来的损害,特别是对眼、肾、心血管及神经系统的损害;并具有抗癌功效。
具体实施方式
为进一步公开而不是限制本发明,以下结合实例对本发明作进一步的详细说明。
实施例1
一种具有治疗糖尿病功效的灵芝复方颗粒剂,按重量份数计,其主要原料组成为:灵芝10份,破壁灵芝孢子粉8份,桦褐孔菌5份,人参6份,黄花22份,山药32份,知母13份,花粉16份,玄参14份,菟丝子12份,黑豆8份,海马6份,香椿叶4份。
一种制备如上所述的具有治疗糖尿病功效的灵芝复方颗粒剂的方法,包括以下步骤:
1)取灵芝、桦褐孔菌、人参、黄花、山药、知母、花粉、玄参、菟丝子、黑豆、海马和香椿叶,混合均匀,加入9倍重量的水,在85℃煮制45min后,过滤;在滤渣中加入5倍重量的水,在85℃煮制45min后,过滤;合并两次过滤的滤液,在75℃减压浓缩至相对密度为1.1的浸膏;
2)将破壁灵芝孢子粉经紫外灭菌30min后,加入浸膏中;
3)然后在步骤2)的浸膏中加入稀释剂、粘合剂,进行湿法制粒;
4)干燥,整粒,过12目筛,入袋,检验,包装。
采用本实施例1制得的颗粒剂用于临床试验,共观察Ⅱ型糖尿病的患者40例,分为两组,其临床试验结果如下:
受试人群:符合Ⅱ型糖尿病诊断及中医气阴两虚兼热症诊断轻度病情受试者;未避免耽误中度病情或重度病情者治疗,在本复方颗粒剂药效不明确情况下,不选择其作为受试人群;
治疗方案:
试验组:本发明,每次一袋(每袋2.5g),每日三次,饭前半小时服用,疗程四周;
对照组:降糖宁胶囊,每次6粒,每日三次,饭前半小时服用,疗程四周;
试验期间禁止合并服用其他降糖药物,每日提供相同的三餐饮食,尽可能减少其他因素的干扰;
试验组疗效:空腹血糖疗效显效率39.12%,餐后血糖显效率39.08%,中医症状显效率35.63%;
对照组疗效:空腹血糖疗效显效率29.13%,餐后血糖显效率33.50%,中医症状显效率32.61%;
试验过程中未见对心、肝、肾功能及血液系统的毒副作用及不良反应。
实施例2
一种具有治疗糖尿病功效的灵芝复方颗粒剂,按重量份数计,其主要原料组成为:灵芝15份,破壁灵芝孢子粉6份,桦褐孔菌6份,人参5份,黄花25份,山药30份,知母15份,花粉15份,玄参15份,菟丝子11份,黑豆9份,海马5份,香椿叶5份。
一种制备如上所述的具有治疗糖尿病功效的灵芝复方颗粒剂的方法,包括以下步骤:
1)取灵芝、桦褐孔菌、人参、黄花、山药、知母、花粉、玄参、菟丝子、黑豆、海马和香椿叶,混合均匀,加入8倍重量的水,在80℃煮制30min后,过滤;在滤渣中加入6倍重量的水,在80℃煮制40min后,过滤;合并两次过滤的滤液,在80℃减压浓缩至相对密度为1.2的浸膏;
2)将破壁灵芝孢子粉经紫外灭菌30min后,加入浸膏中;
3)然后在步骤2)的浸膏中加入稀释剂、粘合剂,进行湿法制粒;
4)干燥,整粒,过20目筛,检验,包装。
采用本实施例2制得的颗粒剂用于临床试验,共观察Ⅱ型糖尿病的患者56例,其临床试验结果如下:
受试人群:符合Ⅱ型糖尿病诊断及中医气阴两虚兼热症诊断轻度病情受试者;未避免耽误中度病情或重度病情者治疗,在本复方颗粒剂药效不明确情况下,不选择其作为受试人群;
治疗方案:
试验组(30例):本发明,每次一袋(每袋2.5g),每日三次,饭前半小时服用,疗程四周;
对照组(26例):降糖宁胶囊,每次6粒,每日三次,饭前半小时服用,疗程四周;
试验期间禁止合并服用其他降糖药物,每日提供相同的三餐饮食,尽可能减少其他因素的干扰;
试验组疗效:空腹血糖疗效显效率43.56%,餐后血糖显效率42.87%,中医症状显效率45.29%;
对照组疗效:空腹血糖疗效显效率27.54%,餐后血糖显效率30.18%,中医症状显效率29.76%;
试验过程中未见对心、肝、肾功能及血液系统的毒副作用及不良反应。
实施例3
一种具有治疗糖尿病功效的灵芝复方颗粒剂,按重量份数计,其主要原料组成为:灵芝20份,破壁灵芝孢子粉4份,桦褐孔菌7份,人参4份,黄花26份,山药28份,知母17份,花粉14份,玄参16份,菟丝子10份,黑豆10份,海马3份,香椿叶5份。
一种制备如上所述的具有治疗糖尿病功效的灵芝复方颗粒剂的方法,包括以下步骤:
1)取灵芝、桦褐孔菌、人参、黄花、山药、知母、花粉、玄参、菟丝子、黑豆、海马和香椿叶,混合均匀,加入10倍重量的水,在90℃煮制30min后,过滤;在滤渣中加入4倍重量的水,在90℃煮制40min后,过滤;合并两次过滤的滤液,在80℃减压浓缩至相对密度为1.3的浸膏;
2)将破壁灵芝孢子粉经紫外灭菌30min后,加入浸膏中;
3)然后在步骤2)的浸膏中加入稀释剂、粘合剂,进行湿法制粒;
4)干燥,整粒,过20目筛,检验,包装。
采用本实施例3制得的颗粒剂用于临床试验,共观察Ⅱ型糖尿病的患者81例,分为两组,其临床试验结果如下:
受试人群:符合Ⅱ型糖尿病诊断及中医气阴两虚兼热症诊断轻度病情受试者;未避免耽误中度病情或重度病情者治疗,在本复方颗粒剂药效不明确情况下,不选择其作为受试人群;
治疗方案:
试验组(41例):本发明,每次一袋(每袋2.5g),每日三次,饭前半小时服用,疗程四周;
对照组(40例):降糖宁胶囊,每次6粒,每日三次,饭前半小时服用,疗程四周;
试验期间禁止合并服用其他降糖药物,每日提供相同的三餐饮食,尽可能减少其他因素的干扰;
试验组疗效:空腹血糖疗效显效率40.00%,餐后血糖显效率39.87%,中医症状显效率38.56%;
对照组疗效:空腹血糖疗效显效率28.65%,餐后血糖显效率30.64%,中医症状显效率30.87%;
试验过程中未见对心、肝、肾功能及血液系统的毒副作用及不良反应。
以上所述仅为本发明的较佳实施例,凡依本发明申请专利范围所做的均等变化与修饰,皆应属本发明的涵盖范围。
Claims (3)
1.一种具有治疗糖尿病功效的灵芝复方颗粒剂,其特征在于:按重量份数计,其主要原料组成为:灵芝10-20份,破壁灵芝孢子粉4-8份,桦褐孔菌5-7份,人参4-6份,黄花22-26份,山药28-32份,知母13-17份,花粉14-16份,玄参14-16份,菟丝子10-12份,黑豆8-10份,海马3-6份,香椿叶4-5份。
2.根据权利要求1所述的具有治疗糖尿病功效的灵芝复方颗粒剂,其特征在于:按重量份数计,其主要原料组成为:灵芝15份,破壁灵芝孢子粉6份,桦褐孔菌6份,人参5份,黄花25份,山药30份,知母15份,花粉15份,玄参15份,菟丝子11份,黑豆9份,海马5份,香椿叶5份。
3.一种制备如权利要求1或2所述的具有治疗糖尿病功效的灵芝复方颗粒剂的方法,其特征在于:包括以下步骤:
1)取灵芝、桦褐孔菌、人参、黄花、山药、知母、花粉、玄参、菟丝子、黑豆、海马和香椿叶,混合均匀,加入8-10倍重量的水,在80-90℃煮制30-60min后,过滤;在滤渣中加入4-6倍重量的水,在80-90℃煮制40-50min后,过滤;合并两次过滤的滤液,在70-80℃减压浓缩至相对密度为1.1-1.3的浸膏;
2)将破壁灵芝孢子粉经紫外灭菌30min后,加入浸膏中;
3)然后在步骤2)的浸膏中加入稀释剂、粘合剂,进行湿法制粒;
4)干燥,整粒,过12-20目筛,检验,包装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610446034.2A CN106075020A (zh) | 2016-06-21 | 2016-06-21 | 一种具有治疗糖尿病功效的灵芝复方颗粒剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610446034.2A CN106075020A (zh) | 2016-06-21 | 2016-06-21 | 一种具有治疗糖尿病功效的灵芝复方颗粒剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106075020A true CN106075020A (zh) | 2016-11-09 |
Family
ID=57237084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610446034.2A Pending CN106075020A (zh) | 2016-06-21 | 2016-06-21 | 一种具有治疗糖尿病功效的灵芝复方颗粒剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106075020A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107233364A (zh) * | 2017-06-01 | 2017-10-10 | 杭州娃哈哈科技有限公司 | 一种降血糖提取物制备方法 |
CN108635389A (zh) * | 2018-08-02 | 2018-10-12 | 浙江吉天合堂国医国药科技有限公司 | 一种治疗2型糖尿病的中药配方及其冲剂的制备方法 |
CN112790378A (zh) * | 2021-02-01 | 2021-05-14 | 陈礼平 | 一种具有降低三高功效的食用菌功能食品 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1718105A (zh) * | 2005-08-09 | 2006-01-11 | 石泽 | 调节血糖血脂提高代谢机能的药膳保健食品 |
CN104645066A (zh) * | 2013-11-26 | 2015-05-27 | 邵艳艳 | 滋阴补气降糖中药方 |
-
2016
- 2016-06-21 CN CN201610446034.2A patent/CN106075020A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1718105A (zh) * | 2005-08-09 | 2006-01-11 | 石泽 | 调节血糖血脂提高代谢机能的药膳保健食品 |
CN104645066A (zh) * | 2013-11-26 | 2015-05-27 | 邵艳艳 | 滋阴补气降糖中药方 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107233364A (zh) * | 2017-06-01 | 2017-10-10 | 杭州娃哈哈科技有限公司 | 一种降血糖提取物制备方法 |
CN108635389A (zh) * | 2018-08-02 | 2018-10-12 | 浙江吉天合堂国医国药科技有限公司 | 一种治疗2型糖尿病的中药配方及其冲剂的制备方法 |
CN112790378A (zh) * | 2021-02-01 | 2021-05-14 | 陈礼平 | 一种具有降低三高功效的食用菌功能食品 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1245187C (zh) | 一种治疗由脏腑病所致眼病的药物 | |
CN105749179A (zh) | 治疗代谢综合征的中药组合物 | |
CN102293927B (zh) | 具有抗疲劳和抗氧化功能的复方中药制剂及其制备方法 | |
CN105920514A (zh) | 治疗代谢综合征的中药组合物 | |
CN104288412B (zh) | 一种治疗代谢综合征的中药组合物 | |
CN101856405B (zh) | 一种治疗2型糖尿病的药物组合物及其制备方法 | |
CN106075020A (zh) | 一种具有治疗糖尿病功效的灵芝复方颗粒剂 | |
CN104905267A (zh) | 一种决明子降血脂保健口服液及其制备方法 | |
CN102813870B (zh) | 一种治疗酒精中毒痛风的中药复方制剂及制备方法与应用 | |
CN101095768B (zh) | 一种治疗中老年原发性高血压的中药胶囊 | |
CN101306138B (zh) | 一种治疗胸痹心痛的中药制剂及其制备方法 | |
CN104083640A (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN105999058B (zh) | 鬼针草降脂片 | |
CN105056103A (zh) | 一种辅助降血脂降胆固醇的馒头及其制备方法 | |
CN104857210A (zh) | 一种治疗脂肪肝的中药组合制剂及其制备方法 | |
CN102274396B (zh) | 治疗糖尿病肾病的中药及其制备方法 | |
CN102228620B (zh) | 一种补铁补血的中药复方制剂及其制备方法 | |
CN103933538A (zh) | 用于治疗脾肾阳虚型肝硬化腹水的药物及其制备方法 | |
CN100528186C (zh) | 一种治疗慢性肾功能衰竭中药复方注射剂的制备工艺以及应用 | |
CN105920371A (zh) | 一种具有降三高功效的灵芝复方制剂 | |
CN104666689A (zh) | 一种治疗高血压的药物 | |
CN105998098A (zh) | 一种制备治疗糖尿病肾病的中药组合物的方法 | |
CN107913389A (zh) | 一种治疗甲状腺肿大的中药组合物及其制备方法 | |
CN102085274A (zh) | 中药治疗急慢性亚级型白血病的组合及其制备方法 | |
CN102274358B (zh) | 一种治疗月经提前量多乳房胀痛血块多的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161109 |
|
RJ01 | Rejection of invention patent application after publication |